Einzeltreffer — DigiBib

Background: Cancer has become a public health problem with high morbidity and mortality. Recent publications have shown that exosomes can be used as potential diagnostic biomarkers of cancer. However, the diagnostic accuracy and reliability of circulating exosomes remain unclear. The present meta-analysis was conducted to comprehensively summarize the overall diagnostic performance of circulating exosomes for cancer.

Methods: Eligible studies published up to June 27, 2019, on PubMed, Embase, and Cochrane Library were selected for the meta-analysis. All statistical analyses were performed by STATA 15.1 statistical software and Meta-DiSc 1.4. Quality Assessment for Studies of Diagnostic Accuracy 2 tool was used to access the quality of included studies. A bivariate mixed-effects model was applied to calculate the diagnostic indexes from included studies.

Results: A total of 5924 participants comprising 3161 cases and 2763 controls from 42 eligible studies were analyzed. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and the area under the curve with 95% confidence intervals (95% CI) were as follows: 0.79 (0.75-0.82), 0.81 (0.78-0.84), 4.1 (3.5-4.8), 0.26 (0.22-0.31), 16 (12-21), and 0.87 (0.84-0.89), respectively. Sensitivity analysis suggested no study exclusively contributed to the heterogeneity, and Deeks' funnel plot asymmetry test indicated no potential publication bias (P = .09).

Conclusions: The meta-analysis indicated that circulating exosomes could serve as effective and minimally invasive biomarkers for diagnosis of cancer, especially in patients with hepatocellular carcinoma or ovarian cancer, serum-based samples and exosomal proteins.

Titel:	Diagnostic performance of circulating exosomes in human cancer: A meta-analysis.
Autor/in / Beteiligte Person:	Guo, D ; Yuan, J ; Xie, A ; Lin, Z ; Li, X ; Chen, J
Link:	Full Text Finder (Volltext)
Zeitschrift:	Journal of clinical laboratory analysis, Jg. 34 (2020-08-01), Heft 8, S. e23341
Veröffentlichung:	Hoboken, N.J. : Wiley ; <i>Original Publication</i>: New York : Alan R. Liss, Inc., c1987-, 2020
Medientyp:	academicJournal
ISSN:	1098-2825 (electronic)
DOI:	10.1002/jcla.23341
Schlagwort:	Humans Biomarkers, Tumor blood Exosomes Neoplasms blood Neoplasms diagnosis
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Meta-Analysis Language: English [J Clin Lab Anal] 2020 Aug; Vol. 34 (8), pp. e23341. <i>Date of Electronic Publication: </i>2020 Apr 20. MeSH Terms: Exosomes* ; Neoplasms* / blood ; Neoplasms* / diagnosis ; Biomarkers, Tumor / *blood ; Humans References: Cell Commun Signal. 2019 Jan 7;17(1):1. (PMID: 30616541) ; Genet Test Mol Biomarkers. 2019 Apr;23(4):235-240. (PMID: 30986097) ; World J Surg Oncol. 2013 Sep 04;11:219. (PMID: 24007214) ; J Cancer. 2018 Jun 23;9(15):2659-2665. (PMID: 30087706) ; Cancer Med. 2018 May;7(5):1670-1679. (PMID: 29573235) ; Cell Death Dis. 2018 Oct 10;9(10):1037. (PMID: 30305607) ; J Extracell Vesicles. 2013 May 27;2:. (PMID: 24009894) ; Theranostics. 2017 Jan 26;7(3):789-804. (PMID: 28255367) ; Circ Res. 2017 May 12;120(10):1632-1648. (PMID: 28495994) ; Biochem Biophys Res Commun. 2017 Aug 19;490(2):406-414. (PMID: 28623135) ; Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):746-754. (PMID: 29739748) ; Cancer Sci. 2018 May;109(5):1701-1709. (PMID: 29573061) ; Clin Chem Lab Med. 2018 Feb 23;56(3):479-484. (PMID: 29252188) ; Eur Urol Focus. 2018 Apr;4(3):412-419. (PMID: 28753793) ; Mol Cancer. 2017 Aug 25;16(1):143. (PMID: 28841829) ; J Neurooncol. 2018 Jan;136(1):51-62. (PMID: 29076001) ; Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):710-716. (PMID: 29650788) ; Eur J Intern Med. 2007 May;18(3):175-84. (PMID: 17449388) ; CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949) ; Ann Intern Med. 2011 Oct 18;155(8):529-36. (PMID: 22007046) ; World J Clin Cases. 2019 Jan 26;7(2):171-190. (PMID: 30705894) ; J Cell Physiol. 2019 Feb;234(2):1416-1425. (PMID: 30078189) ; J Cell Biochem. 2018 Nov;119(10):8600-8610. (PMID: 30015383) ; J Cell Physiol. 2019 Nov;234(11):20721-20727. (PMID: 31032916) ; Mol Ther Nucleic Acids. 2018 Sep 7;12:229-241. (PMID: 30195762) ; J Ovarian Res. 2019 Jan 22;12(1):6. (PMID: 30670062) ; Hematol Oncol. 2018 Dec;36(5):786-791. (PMID: 30144133) ; Expert Rev Proteomics. 2009 Jun;6(3):267-83. (PMID: 19489699) ; Pathol Res Pract. 2019 Aug;215(8):152466. (PMID: 31146974) ; Med Sci Monit. 2018 Dec 21;24:9307-9316. (PMID: 30576305) ; Mol Cancer Ther. 2019 Feb;18(2):459-469. (PMID: 30413650) ; Mol Carcinog. 2018 Sep;57(9):1223-1236. (PMID: 29749061) ; Mol Cancer. 2018 Feb 27;17(1):68. (PMID: 29486794) ; Clin Chim Acta. 2016 Feb 15;454:28-32. (PMID: 26724367) ; Oncotarget. 2016 Dec 20;7(51):85551-85563. (PMID: 27888803) ; Neuro Oncol. 2014 Apr;16(4):520-7. (PMID: 24435880) ; PLoS One. 2017 Mar 10;12(3):e0171810. (PMID: 28282381) ; Cancer Sci. 2019 Jan;110(1):433-442. (PMID: 30407700) ; CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. (PMID: 26808342) ; BMC Cancer. 2018 Jan 31;18(1):116. (PMID: 29385987) ; J Cancer Res Clin Oncol. 2017 Jun;143(6):991-1004. (PMID: 28285404) ; Med Oncol. 2014 Sep;31(9):148. (PMID: 25099764) ; J Cell Biochem. 2019 Feb;120(2):1492-1502. (PMID: 30304555) ; PLoS One. 2015 Oct 06;10(10):e0140067. (PMID: 26441340) ; J Clin Lab Anal. 2020 Aug;34(8):e23341. (PMID: 32309888) ; Methods Mol Biol. 2016;1381:111-49. (PMID: 26667458) ; Hepatogastroenterology. 2006 Jan-Feb;53(67):1-4. (PMID: 16506366) ; Oncotarget. 2016 Mar 29;7(13):16923-35. (PMID: 26943577) ; Mol Cancer. 2018 Oct 3;17(1):143. (PMID: 30285771) ; J Clin Med. 2019 May 16;8(5):. (PMID: 31100935) ; J Cancer. 2019 May 12;10(9):1958-1967. (PMID: 31205555) ; Nature. 2015 Jul 9;523(7559):177-82. (PMID: 26106858) ; Curr Opin Cell Biol. 2009 Aug;21(4):575-81. (PMID: 19442504) ; J Thorac Oncol. 2016 Oct;11(10):1701-10. (PMID: 27343445) ; J Proteomics. 2010 Sep 10;73(10):1907-20. (PMID: 20601276) ; Cell Physiol Biochem. 2018;46(2):532-545. (PMID: 29614511) ; Cancer Med. 2019 Jul;8(7):3566-3574. (PMID: 31099496) ; J Cancer Res Ther. 2014 Nov;10 Suppl:C222-4. (PMID: 25450287) ; Clin Lab. 2019 May 1;65(5):. (PMID: 31115208) ; Mol Cancer. 2018 Apr 24;17(1):84. (PMID: 29690888) ; BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120) Contributed Indexing: Keywords: cancer; carcinoma; circulating; diagnosis; exosome; meta-analysis Substance Nomenclature: 0 (Biomarkers, Tumor) Entry Date(s): Date Created: 20200421 Date Completed: 20210621 Latest Revision: 20240329 Update Code: 20240329 PubMed Central ID: PMC7439344

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Diagnostic performance of circulating exosomes in human cancer: A meta-analysis.